NCT05688306View on ClinicalTrials.gov

To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment

CompletedOBSERVATIONAL

Enrollment

3,494

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions

Chemotherapy-induced Thrombocytopenia

Interventions

DRUG

Recombinant Human Interleukin-11 for Injection

received rhIL-11 injection for at least 5 consecutive days

Trial Locations (1)

110000

Xing Xiaojing, Shenyang

All Listed Sponsors

lead

Liaoning Cancer Hospital & Institute

OTHER

NCT05688306 - To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment | Biotech Hunter | Biotech Hunter